Project Grant K23HL171636
Award Date
8/5/24
Completion Date
7/31/29
Dollars Obligated
$199K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $817,208 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Broad Institute, Inc. The grant will fund research to investigate the genetic basis and underlying mechanisms of heart failure using high-throughput cellular assays. The research aims to accelerate the functional interpretation of genes associated with heart failure risk identified through genome-wide association studies. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...
This federal Project Grant award, with ID R01HL174996, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $699,133 award supports research to understand the epigenetic regulation and transcriptomic reprogramming that underlie the development of heart failure with preserved ejection fraction (HFPEF) across multiple organ systems, including the heart, kidney, and liver. The researchers will leverage a rat...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $2,369,201 and supports research to evaluate the impact of non-COPD medications on chronic obstructive pulmonary disease (COPD) management. The primary goal is to develop a population-based data infrastructure and analytical framework to robustly and validly assess the effects of existing drugs, beyond those specifically indicated for COPD,...
This $732,779 Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research focused on understanding the role of the serine-threonine kinase SGK1 in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The University of Arizona, as the prime awardee, will conduct studies to determine how cardiac-specific SGK1 regulates heart function, metabolism, and inter-organ...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $777,954 to the Icahn School of Medicine at Mount Sinai to conduct a mixed-method study on the association between school environment attributes, adolescent cardiovascular risk, and maternal morbidity. The study aims to create a school-based adolescent preconception cohort by leveraging existing data, engage adolescents and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...